Antibody response to mycobacterial Rpf B protein and its immunodominant peptides in HIV-TB co-infected individuals

IF 2.8 3区医学 Q3 IMMUNOLOGY Tuberculosis Pub Date : 2023-12-16 DOI:10.1016/j.tube.2023.102464

Madhur Kalyan , Sumedha Sharma , Prabhdeep Kaur , Aman Sharma , Indu Verma

引用次数: 0

Abstract

Diagnosis of TB at early stages of HIV infection may lead to timely intervention for improving patient outcome. Antibodies to Mycobacterium tuberculosis recombinant RpfB protein and two immunodominant peptides of Rpf B protein were evaluated in the sera of HIV ⁺TB⁺, HIV⁺ and HIV⁻ pulmonary TB patients by ELISA. Serum antibodies from 90 % and 65 % of HIV⁺TB⁺ patients reacted to recombinant RpfB protein and synthetic peptide RpfP1 respectively. Overall, this study shows that resuscitation promoting factor B elicits humoral antibody response in HIV⁺TB⁺ co-infected individuals and be proposed as a potential biomarker for diagnosis of HIV⁺TB⁺ patients, however further longitudinal follow up studies are warranted.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

艾滋病毒-结核病合并感染者对分枝杆菌 Rpf B 蛋白及其免疫优势肽的抗体反应

在艾滋病病毒感染的早期阶段诊断出结核病，可以及时采取干预措施，改善患者的预后。通过 ELISA 方法评估了 HIV + TB+、HIV+ 和 HIV- 肺结核患者血清中结核分枝杆菌重组 RpfB 蛋白和 Rpf B 蛋白两种免疫优势肽的抗体。90% 和 65% 的 HIV-TB 患者的血清抗体分别对重组 RpfB 蛋白和合成肽 RpfP1 起反应。总之，这项研究表明，促进复苏因子 B 可引起 HIV+TB+ 合并感染者的体液抗体反应，可作为诊断 HIV+TB+ 患者的潜在生物标志物，但还需要进一步的纵向跟踪研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Tuberculosis 医学-呼吸系统

CiteScore

4.60

自引率

3.10%

发文量

审稿时长

49 days

期刊介绍： Tuberculosis is a speciality journal focusing on basic experimental research on tuberculosis, notably on bacteriological, immunological and pathogenesis aspects of the disease. The journal publishes original research and reviews on the host response and immunology of tuberculosis and the molecular biology, genetics and physiology of the organism, however discourages submissions with a meta-analytical focus (for example, articles based on searches of published articles in public electronic databases, especially where there is lack of evidence of the personal involvement of authors in the generation of such material). We do not publish Clinical Case-Studies. Areas on which submissions are welcomed include: -Clinical TrialsDiagnostics- Antimicrobial resistance- Immunology- Leprosy- Microbiology, including microbial physiology- Molecular epidemiology- Non-tuberculous Mycobacteria- Pathogenesis- Pathology- Vaccine development. This Journal does not accept case-reports. The resurgence of interest in tuberculosis has accelerated the pace of relevant research and Tuberculosis has grown with it, as the only journal dedicated to experimental biomedical research in tuberculosis.